PE20152007A1 - Entidades quimicas - Google Patents
Entidades quimicasInfo
- Publication number
- PE20152007A1 PE20152007A1 PE2015001900A PE2015001900A PE20152007A1 PE 20152007 A1 PE20152007 A1 PE 20152007A1 PE 2015001900 A PE2015001900 A PE 2015001900A PE 2015001900 A PE2015001900 A PE 2015001900A PE 20152007 A1 PE20152007 A1 PE 20152007A1
- Authority
- PE
- Peru
- Prior art keywords
- heteroaryl
- aryl
- compounds
- treatment
- chemical entities
- Prior art date
Links
- 150000005829 chemical entities Chemical class 0.000 title 1
- -1 R2 is NR3S = 2R3 Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 210000004696 endometrium Anatomy 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 201000001441 melanoma Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 210000001672 ovary Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Abstract
Referida a compuestos triciclicos de formula (I), en donde R1 es arilo o heteroarilo, R2 es NR3S=2R3, alquilo, cicloalquilo, arilo o heteroarilo y m es 1 o 2; asi como a sus sales, solvatos y estereoisomeros farmaceuticamente aceptables de los mismos. Estos compuestos son inhibidores de cinasa de ataxia telangiectasia mutada y relacionada con Rad3 (ATR) y son potencialmente utiles en el tratamiento del cancer, principalmente de pulmon, prostata, melanoma, ovario, mama, endometrio, entre otros. Tambien esta referida a composiciones farmaceuticas, productos de combinacion y procedimientos de tratamiento que usan estas composiciones
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382089 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20152007A1 true PE20152007A1 (es) | 2016-02-04 |
Family
ID=48013903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015001900A PE20152007A1 (es) | 2013-03-15 | 2014-03-14 | Entidades quimicas |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9453031B2 (es) |
| EP (1) | EP2970332B1 (es) |
| JP (1) | JP6379115B2 (es) |
| KR (1) | KR102206318B1 (es) |
| CN (1) | CN105051047B (es) |
| AR (1) | AR095443A1 (es) |
| AU (1) | AU2014229735B2 (es) |
| BR (1) | BR112015023060B1 (es) |
| CA (1) | CA2904768C (es) |
| CL (1) | CL2015002591A1 (es) |
| CY (1) | CY1120619T1 (es) |
| DK (1) | DK2970332T3 (es) |
| EA (1) | EA029771B1 (es) |
| ES (1) | ES2670674T3 (es) |
| HR (1) | HRP20180839T1 (es) |
| HU (1) | HUE037685T2 (es) |
| IL (1) | IL240708B (es) |
| LT (1) | LT2970332T (es) |
| MX (1) | MX368056B (es) |
| NO (1) | NO2970332T3 (es) |
| NZ (1) | NZ711038A (es) |
| PE (1) | PE20152007A1 (es) |
| PH (1) | PH12015502159B1 (es) |
| PL (1) | PL2970332T3 (es) |
| PT (1) | PT2970332T (es) |
| RS (1) | RS57216B1 (es) |
| SG (1) | SG11201507555PA (es) |
| SI (1) | SI2970332T1 (es) |
| TW (1) | TWI557131B (es) |
| UA (1) | UA118261C2 (es) |
| WO (1) | WO2014140644A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2649156T3 (es) | 2013-01-14 | 2018-01-10 | Incyte Holdings Corporation | Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim |
| TW201932456A (zh) | 2013-01-15 | 2019-08-16 | 美商英塞特控股公司 | 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物 |
| MX2016002367A (es) | 2013-08-23 | 2016-10-28 | Incyte Corp | Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim. |
| WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016112374A2 (en) * | 2015-01-09 | 2016-07-14 | The General Hospital Corporation | Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| US10570149B2 (en) | 2016-05-24 | 2020-02-25 | Merck Patent Gmbh | Tricyclic heterocylic derivatives |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| IL276489B2 (en) * | 2018-02-07 | 2024-09-01 | Shijiazhuang Sagacity New Drug Dev Company Ltd | Atr inhibitor and application thereof |
| WO2020094084A1 (zh) * | 2018-11-07 | 2020-05-14 | 南京明德新药研发有限公司 | 作为ret抑制剂的三并环衍生物 |
| CN113004303A (zh) * | 2019-12-18 | 2021-06-22 | 江苏恒瑞医药股份有限公司 | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 |
| WO2021143821A1 (zh) * | 2020-01-17 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 |
| WO2022078480A1 (zh) | 2020-10-16 | 2022-04-21 | 上海迪诺医药科技有限公司 | 三杂环衍生物、其药物组合物及应用 |
| CN115466258A (zh) * | 2021-06-11 | 2022-12-13 | 成都苑东生物制药股份有限公司 | Atr抑制剂及其用途 |
| CN115286645A (zh) * | 2022-08-16 | 2022-11-04 | 南京雷正医药科技有限公司 | 三环杂环衍生物及其药物组合物和用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| AU3427093A (en) * | 1992-01-15 | 1993-08-03 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| US20020192228A1 (en) | 1997-02-12 | 2002-12-19 | Samir M. Hanash | Protein markers for lung cancer and use thereof |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| PL205557B1 (pl) | 1999-02-10 | 2010-05-31 | Astrazeneca Ab | Pochodne indolu |
| AU769222B2 (en) | 1999-11-05 | 2004-01-22 | Genzyme Corporation | Quinazoline derivatives as VEGF inhibitors |
| MY130363A (en) | 2000-02-15 | 2007-06-29 | Sugen Inc | "pyrrole substituted 2-indolinone protein kinase inhibitors" |
| BR0111230A (pt) | 2000-05-31 | 2003-06-10 | Astrazeneca Ab | Composto, e, uso e processo para a preparação do mesmo |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
| US8735411B2 (en) * | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
| CA2667960A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Imidazopyridazines as pi3k lipid kinase inhibitors |
| AR066477A1 (es) * | 2007-05-09 | 2009-08-19 | Novartis Ag | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido |
| MX2012002059A (es) * | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. |
| CN102020657A (zh) * | 2009-09-11 | 2011-04-20 | 上海艾力斯医药科技有限公司 | 稠合杂芳基衍生物、制备方法及其应用 |
| US8623869B2 (en) * | 2010-06-23 | 2014-01-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| AU2011343712B2 (en) * | 2010-12-16 | 2015-09-17 | Genentech, Inc. | Tricyclic PI3k inhibitor compounds and methods of use |
-
2014
- 2014-03-13 AR ARP140100990A patent/AR095443A1/es unknown
- 2014-03-14 SI SI201430698T patent/SI2970332T1/en unknown
- 2014-03-14 RS RS20180576A patent/RS57216B1/sr unknown
- 2014-03-14 MX MX2015011549A patent/MX368056B/es active IP Right Grant
- 2014-03-14 PT PT147169106T patent/PT2970332T/pt unknown
- 2014-03-14 LT LTEP14716910.6T patent/LT2970332T/lt unknown
- 2014-03-14 PE PE2015001900A patent/PE20152007A1/es active IP Right Grant
- 2014-03-14 AU AU2014229735A patent/AU2014229735B2/en active Active
- 2014-03-14 US US14/774,294 patent/US9453031B2/en active Active
- 2014-03-14 PL PL14716910T patent/PL2970332T3/pl unknown
- 2014-03-14 HR HRP20180839TT patent/HRP20180839T1/hr unknown
- 2014-03-14 BR BR112015023060-1A patent/BR112015023060B1/pt active IP Right Grant
- 2014-03-14 KR KR1020157025265A patent/KR102206318B1/ko not_active Expired - Fee Related
- 2014-03-14 CN CN201480015613.0A patent/CN105051047B/zh active Active
- 2014-03-14 UA UAA201510054A patent/UA118261C2/uk unknown
- 2014-03-14 CA CA2904768A patent/CA2904768C/en active Active
- 2014-03-14 ES ES14716910.6T patent/ES2670674T3/es active Active
- 2014-03-14 NZ NZ711038A patent/NZ711038A/en not_active IP Right Cessation
- 2014-03-14 SG SG11201507555PA patent/SG11201507555PA/en unknown
- 2014-03-14 EA EA201591781A patent/EA029771B1/ru not_active IP Right Cessation
- 2014-03-14 JP JP2015562337A patent/JP6379115B2/ja active Active
- 2014-03-14 DK DK14716910.6T patent/DK2970332T3/en active
- 2014-03-14 HU HUE14716910A patent/HUE037685T2/hu unknown
- 2014-03-14 WO PCT/GB2014/050825 patent/WO2014140644A1/en not_active Ceased
- 2014-03-14 EP EP14716910.6A patent/EP2970332B1/en active Active
- 2014-03-14 NO NO14716910A patent/NO2970332T3/no unknown
- 2014-03-14 TW TW103109396A patent/TWI557131B/zh not_active IP Right Cessation
-
2015
- 2015-08-20 IL IL240708A patent/IL240708B/en active IP Right Grant
- 2015-09-10 CL CL2015002591A patent/CL2015002591A1/es unknown
- 2015-09-15 PH PH12015502159A patent/PH12015502159B1/en unknown
-
2018
- 2018-05-24 CY CY181100555T patent/CY1120619T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20152007A1 (es) | Entidades quimicas | |
| ECSP22091792A (es) | Compuestos tricíclicos sustituidos como inhibidores del receptor del factor de crecimiento de fibroplastos | |
| MX2018013433A (es) | Piperidinas como inhibidores de menina. | |
| CL2017000521A1 (es) | Inhibidores de desmetilasa-1 específica a lisina | |
| PE20151417A1 (es) | Inhibidores de histona desmetilasa | |
| CL2012000324A1 (es) | Compuestos derivados de benciimidazol sustituido con un grupo pirazol sustituido, inhibidor de quinasa fgfr; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer. | |
| MX2018012379A (es) | Degradadores de proteinas de bromodominio y dominioextraterminal (bet). | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| CL2015003491A1 (es) | Compuestos químicos. | |
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CU20160162A7 (es) | Derivados de pirrolidina-2,5-diona,para usar como inhibidores ido1 y composiciones farmacéuticas que los contienen | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| ECSP088820A (es) | Síntesis de acil-amino-alquenilen-amidas utiles como antagonistas de la sustancia p. | |
| UY35975A (es) | Macrociclos con grupos p2? heterocíclicos como inhibidores del factor xia | |
| UY34393A (es) | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor xia | |
| UY34825A (es) | Síntesis de compuestos heterocíclicos | |
| CR20170596A (es) | Derivados de amidas policiclicas como inhibidores de cdk9 | |
| PE20141381A1 (es) | Terapia de combinacion que comprende un inhibidor de cdk4/6 y un inhibidor de pi3k para el uso en el tratamiento de cancer | |
| CL2015001246A1 (es) | Derivados de bendamustina y los metodos de su uso | |
| UY31689A1 (es) | Derivados de platino-carbeno n-heterocíclico, su preparación y su aplicación en terapéutica | |
| MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
| MX391999B (es) | Piridinas y su uso en el tratamiento del cáncer. | |
| CY1120142T1 (el) | Ενωσεις αζετιδινυλοξυφαινυλοπυρρολiδινης | |
| PE20190376A1 (es) | Combinaciones farmaceuticas para el tratamiento del cancer | |
| MX392000B (es) | Piridinas sustituidas con heteroarilsulfonilo y su uso en el tratamiento del cáncer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |